Direct Health Care Costs Associated With Multiple Sclerosis

Amir Khakban; Elisabet Rodríguez Llorian; Kristina D. Michaux; Scott Burton Patten; Anthony Traboulsee; Jiwon Oh; Larry D. Lynd

doi:10.1212/wnl.0000000000201645

Abstract

1 min read

The economic burden of MS is considerable, with medications, particularly DMTs, being the largest cost driver. Future studies should investigate how disease management strategies, including early diagnosis and timely use of DMTs, could offset future and ongoing costs while improving patients' quality of life.

Related publications

Article2022

Cost‐of‐Illness Analysis of Long‐Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry

Ioannis T. Farmakis, Stefano Barco, Anna C. Mavromanoli, Giancarlo Agnelli, Alexander T. Cohen, George Giannakoulas, Charles E. Mahan, Stavros Konstantinides, Luca Valerio

Article2022

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion

Massimo Filippi, Maria Pia Amato, Diego Centonze, Paolo Gallo, Claudio Gasperini, Matilde Inglese, Francesco Patti, Carlo Pozzilli, Paolo Preziosa, María Trojano

Article2018

In‐hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation

Sanshuai Chang, Jiahui Wu, Yi Liu, Ting Zhang, Xin Du, Jianzeng Dong, Professor Gregory Lip, Changsheng Ma

Article2020

Rethinking MS in Europe Prioritising Timely Integrated Services for People with Multiple Sclerosis

Mónica Di Luca, Claudio L. Bassetti, Joke Jaarsma, Per Soelberg Sørensen, Maura Pugliatti, Mario Alberto Battaglia, Cristina Tiu, Ludwig Kappos, Massimo Filippi, Hans‐Peter Hartung, Gıancarlo Comı, Jenny Freeman, Kerstin Hellwig, Elisabeth Kasilingam, P Carrascal, Vinciane Quoidbach

Article1996

The costs of asthma

Peter J Barnes, Bengt Jønsson, JB Klim